Women Who Lose Weight on Ozempic Are Judged More Harshly. A New Study Measured How Much.
Women who lose weight using GLP-1 medications like Ozempic or Wegovy face more social judgment than women who lose the same amount of weight through diet and exercise. A new study out of George Washington University put numbers to it.
The study, published April 9 in Stigma & Health, recruited 402 U.S. women ages 30 to 49 who identified as Black or white and reported being overweight or having obesity. Participants read a vignette about a fictional woman, Evette, who had lost 15% of her body weight, either through diet and exercise, or with a GLP-1 medication. They then rated her on fat phobia, dislike, blame, and desire for social distance.
No spam. Unsubscribe anytime.
The results: Evette was rated more harshly when she used medication. The key driver was not the weight loss itself. It was the belief that she had taken a "shortcut." Participants who endorsed that framing were more likely to report higher fat phobia, more blame, and greater desire for social distance from her.
That finding is not entirely surprising. What was unexpected: the stigma was stronger when Evette was depicted as a white woman than as a Black woman. The researchers do not fully explain why, flagging it as a finding that warrants further study. Also notable: the race of the study participants did not significantly affect stigma levels, suggesting the "shortcut" assumption may operate similarly across groups.
A few caveats worth noting. This was an experimental vignette study. Participants were reacting to a fictional scenario, not a real person in their lives. Whether these measured attitudes translate into real-world behavior toward GLP-1 users is a separate question the study does not answer. The sample was also limited to women who identified as Black or white, and all participants themselves reported being overweight or having obesity, which may shape their responses in ways that would not generalize to the broader population.
The researchers, led by Stacy Post, PhD, a postdoctoral researcher at Georgetown's Lombardi Comprehensive Cancer Center, argue the findings have practical stakes. Weight stigma is associated with stress, depression, and avoidance of care. If women anticipate social judgment for taking a prescribed medication, some may avoid it, even when it is clinically appropriate.
"Treatment decisions should be guided by health, not judgments about how someone manages their weight," Post said in a statement. "Reducing stigma means challenging the idea that there is only one 'right' way to lose weight."
More than 100 million Americans are clinically eligible for GLP-1 medications, and roughly 18% of U.S. adults report currently using or having previously used one. As that number grows, so does the social terrain around it, and apparently, the judgment.
Source: "Social Perceptions of GLP-1-assisted Weight Loss in Black and White Women with Obesity," Stigma & Health, April 9, 2026. Georgetown University Medical Center / George Washington University / National Human Genome Research Institute.